Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Usmani, Saad
Item TypeName
Concept Drug Administration Schedule
Concept Administration, Cutaneous
Concept Drug Administration Routes
Academic Article Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Academic Article Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Academic Article Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
Academic Article Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Academic Article Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Academic Article Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Academic Article Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Academic Article Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Academic Article Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Academic Article An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Academic Article Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
Academic Article Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
Academic Article Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Academic Article Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Academic Article Teclistamab, a B-cell maturation antigen?×?CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Concept Administration, Metronomic
Concept Administration, Intravenous
Search Criteria
  • Organization and Administration